Antihypertensive Drugs and the Sympathetic Nervous System

Hypertension has been associated with several modifications in the function and regulation of the sympathetic nervous system (SNS). Although it is unclear whether this dysfunction is primary or secondary to the development of hypertension, these alterations are considered to play an important role in the evolution, maintenance, and development of hypertension and its target organ damage. Several pharmacological antihypertensive classes are currently available. The main drugs that have been clearly shown to affect SNS function are β-blockers, α-blockers, and centrally acting drugs. On the contrary, the effects of ACE inhibitors (ACE-Is), AT1 receptor blockers (ARBs), calcium channel blockers (CCBs), and diuretics on SNS function remain controversial. These properties are pharmacologically and pathophysiologically relevant and should be considered in the choice of antihypertensive treatments and combination therapies in order to achieve, beyond optimal blood pressure control, a normalization of SNS physiology and the most effective prevention of target organ damage.

[1]  T. Hedner,et al.  Circulatory effects of noise. , 2009, Acta medica Scandinavica.

[2]  L. Hansson,et al.  Circulatory effects of stress in essential hypertension. , 2009, Acta medica Scandinavica. Supplementum.

[3]  P. Blankestijn,et al.  Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment , 2007, Hypertension.

[4]  D. Su,et al.  Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs. , 2006, European journal of pharmacology.

[5]  G. Lembo,et al.  Characterization of nitric oxide release by nebivolol and its metabolites. , 2006, American journal of hypertension.

[6]  H. Krum,et al.  Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. , 2006, American journal of physiology. Heart and circulatory physiology.

[7]  F. Leenen,et al.  Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release , 2006, Journal of hypertension.

[8]  R. Fogari,et al.  Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. , 2005, American journal of hypertension.

[9]  J. Standridge Hypertension and atherosclerosis: Clinical implications from the ALLHAT trial , 2005, Current atherosclerosis reports.

[10]  R. Martuzzi,et al.  Bradykinin B2 receptor gene (−58T/C) polymorphism influences baroreflex sensitivity in never-treated hypertensive patients , 2005, Journal of Hypertension.

[11]  S. Douma,et al.  Different Effects of Losartan and Moxonidine on Endothelial Function During Sympathetic Activation in Essential Hypertension , 2004, Journal of clinical hypertension.

[12]  D. Alexopoulos,et al.  Autonomic Effects of Nebivolol versus Atenolol in Healthy Subjects , 2004, Cardiovascular Drugs and Therapy.

[13]  G. Grassi Sympathetic and baroreflex function in hypertension: implications for current and new drugs. , 2004, Current pharmaceutical design.

[14]  J. Greenwood,et al.  Arterial Pressure Lowering Effect of Chronic Atenolol Therapy in Hypertension and Vasoconstrictor Sympathetic Drive , 2004, Hypertension.

[15]  G. Jennings,et al.  Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion , 2004, Journal of hypertension.

[16]  G. Grassi,et al.  Central sympatholytic drugs for the treatment of hypertension: back to the future? , 2004, Journal of hypertension.

[17]  G. Grassi Neuroadrenergic effects of calcium channel blockers: a developing concept. , 2004, Journal of hypertension.

[18]  J. Floras,et al.  Effects of low-dose nifedipine GITS on sympathetic activity in young and older patients with hypertension , 2004, Journal of hypertension.

[19]  G. Head,et al.  Sympathetic Responses to Stress and Rilmenidine in 2K1C Rabbits: Evidence of Enhanced Nonvascular Effector Mechanism , 2004, Hypertension.

[20]  T. Walther,et al.  Carvedilol-induced antagonism of angiotensin II: a matter of α1-adrenoceptor blockade , 2004 .

[21]  K. Kanmatsuse,et al.  Effect of Morning and Bedtime Dosing with Cilnidipine on Blood Pressure, Heart Rate, and Sympathetic Nervous Activity in Essential Hypertensive Patients , 2004, Journal of cardiovascular pharmacology.

[22]  G. Mancia,et al.  Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study , 2003, Journal of hypertension.

[23]  J. Staessen,et al.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 , 2003, Journal of hypertension.

[24]  G. Mancia,et al.  Short- Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension , 2003, Hypertension.

[25]  M. Pfaffendorf,et al.  Sympatho‐inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar–Kyoto rats , 2003, Fundamental & clinical pharmacology.

[26]  P. Blankestijn,et al.  Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[27]  K. Harada,et al.  Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[28]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[29]  A. Malliani,et al.  Impairment in Cardiac Autonomic Regulation Preceding Arterial Hypertension in Humans: Insights From Spectral Analysis of Beat-by-Beat Cardiovascular Variability , 2002, Circulation.

[30]  G. Noll,et al.  Effects of Chronic Calcium Channel Blockade on Sympathetic Nerve Activity in Hypertension , 2002, Hypertension.

[31]  Z. Wang,et al.  Resetting baroreceptors to a lower arterial pressure level by enalapril avoids baroreflex mediated activation of sympathetic nervous system by nifedipine. , 2001, Life sciences.

[32]  J. Mallion,et al.  Effects of amlodipine on baroreflex and sympathetic nervous system activity in mild-to-moderate hypertension. , 2001, American journal of hypertension.

[33]  H. Krum,et al.  Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension , 2001, Journal of hypertension.

[34]  R. Fogari,et al.  Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension , 2000, Journal of hypertension.

[35]  Y. Kawano,et al.  Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension. , 2000, British journal of clinical pharmacology.

[36]  X. Yang,et al.  The effects of verapamil SR and bisoprolol on reducing the sympathetic nervous system's activity. , 2000, Hypertension research : official journal of the Japanese Society of Hypertension.

[37]  J. Greenwood,et al.  Chronic I(1)-imidazoline agonism : sympathetic mechanisms in hypertension. , 2000, Hypertension.

[38]  M. Esler,et al.  The sympathetic system and hypertension. , 2000, American journal of hypertension.

[39]  Y. Kawano,et al.  Effects of diltiazem retard on ambulatory blood pressure and heart rate variability in patients with essential hypertension , 2000, Blood pressure monitoring.

[40]  N. Bissoli,et al.  The diuretic chlorthalidone normalizes baroreceptor and Bezold-Jarisch reflexes in DOCA-salt hypertensive rats. , 2000, Pharmacological research.

[41]  F. Leenen,et al.  Sympathoinhibition by central and peripheral infusion of nifedipine in spontaneously hypertensive rats. , 2000, Hypertension.

[42]  G. Grassi,et al.  How to assess sympathetic activity in humans. , 1999, Journal of hypertension.

[43]  M. Shirotani,et al.  Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. , 1999, Hypertension.

[44]  J. Nürnberger,et al.  Adrenoceptors mediating the cardiovascular and metabolic effects of alpha-methylnoradrenaline in humans. , 1999, The Journal of pharmacology and experimental therapeutics.

[45]  A. Smit,et al.  Improved short-term blood pressure control by treatment with calcium antagonists in patients with mild to moderate hypertension. , 1999 .

[46]  G. Cerasola,et al.  Inhibition of sympathetic activity induced by losartan in essential hypertensives. , 1999 .

[47]  A. Lechi,et al.  Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. , 1999, Journal of hypertension.

[48]  R. Fogari,et al.  P-8: Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension , 1999 .

[49]  F. Veglio,et al.  Assessment of Heart Rate Variability after Calcium Antagonist and β-Blocker Therapy in Patients with Essential Hypertension , 1999 .

[50]  T. Lüscher,et al.  Endothelin in cardiovascular control: The role of endothelin antagonists , 1999, Current hypertension reports.

[51]  H. Drexler,et al.  Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.

[52]  N. Montano,et al.  Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. , 1998, Journal of the autonomic nervous system.

[53]  T. Lüscher,et al.  I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. , 1998, Hypertension.

[54]  G. Mancia,et al.  Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension , 1998, Journal of hypertension.

[55]  R. Schrier,et al.  Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. , 1998, The American journal of cardiology.

[56]  G Mancia,et al.  Heart rate as marker of sympathetic activity , 1998, Journal of hypertension.

[57]  R. Nadeau,et al.  Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients , 1998, Journal of hypertension.

[58]  Jagmeet P. Singh,et al.  Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. , 1998, Hypertension.

[59]  P. Sleight The sympathetic nervous system in hypertension: differing effects of drug treatment. , 1998, European heart journal.

[60]  K. Airaksinen,et al.  Vagal cardiac activity in essential hypertension: the effects of metoprolol and ramipril. , 1998, American journal of hypertension.

[61]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[62]  L. Ghiadoni,et al.  Effects of angiotensin converting enzyme inhibition on endothelium‐dependent vasodilatation in essential hypertensive patients , 1998, Journal of hypertension.

[63]  W. Koenig,et al.  Comparison of the proximal flow convergence method and the jet area method for the assessment of the severity of tricuspid regurgitation. , 1998, European heart journal.

[64]  P. Schollmeyer,et al.  Experimental evidence to support ELITE , 1998, The Lancet.

[65]  J. Bigger,et al.  Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction , 1998, The Lancet.

[66]  I. Hisatome,et al.  Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine , 1998, Journal of hypertension.

[67]  B. Pitt,et al.  Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction. , 1997, The American journal of cardiology.

[68]  G. Mancia Björn Folkow Award Lecture The sympathetic nervous system in hypertension , 1997, Journal of hypertension.

[69]  M. Hetzel,et al.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). , 1997, Circulation.

[70]  C. Tack,et al.  Long-term beta 1-adrenergic blockade restores adrenomedullary activity in primary hypertension. , 1997, Journal of cardiovascular pharmacology.

[71]  O. Tochikubo,et al.  Doxazosin suppresses the morning increase in blood pressure and sympathetic nervous activity in patients with essential hypertension. , 1997, Hypertension research : official journal of the Japanese Society of Hypertension.

[72]  G. Mancia,et al.  Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. , 1997, Circulation.

[73]  R. Ruffolo,et al.  Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. , 1997, Pharmacology.

[74]  T. Lüscher,et al.  Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. , 1997, Journal of the American College of Cardiology.

[75]  T. Lüscher,et al.  Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. , 1997, Circulation.

[76]  O. Muzik,et al.  Effects of cardiac sympathetic innervation on coronary blood flow. , 1997, The New England journal of medicine.

[77]  D. Calhoun Effects of 4 weeks of amlodipine therapy on muscle sympathetic nerve activity , 1997 .

[78]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[79]  P. A. Zwieten Central imidazoline (I1) receptors as targets of centrally acting antihypertensives : moxonidine and rilmenidine , 1997 .

[80]  M. Michel,et al.  Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[81]  D. Levy,et al.  Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. , 1996, Circulation.

[82]  M. Rocco,et al.  Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.

[83]  G. Dibona,et al.  Effect of endogenous angiotensin II on renal nerve activity and its arterial baroreflex regulation. , 1996, The American journal of physiology.

[84]  Arnold M. Katz Calcium channel diversity in the cardiovascular system. , 1996, Journal of the American College of Cardiology.

[85]  T. Lüscher,et al.  Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. , 1996, Circulation.

[86]  F. Leenen,et al.  Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. , 1996, The American journal of cardiology.

[87]  C. Brilla,et al.  Drug withdrawal and rebound hypertension: Differential action of the central antihypertensive drugs moxonidine and clonidine , 1996, Cardiovascular Drugs and Therapy.

[88]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[89]  G. B. John Mancini,et al.  Angiotensin Converting Enzyme Inhibition, with Quinapril, Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: the TREND Study (Trial on REversing ENdothelial Dysfunction) , 1996 .

[90]  T. Lüscher,et al.  Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. , 1996, Circulation.

[91]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[92]  H. Drexler,et al.  Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. , 1995, The American journal of cardiology.

[93]  S. Kjeldsen,et al.  Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? , 1995, Journal of human hypertension.

[94]  B. Pitt,et al.  Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial , 1995, Cardiovascular Drugs and Therapy.

[95]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[96]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[97]  J. Reid,et al.  Clinical Pharmacology of Drugs Acting on Imidazoline and Adrenergic Receptors , 1995, Annals of the New York Academy of Sciences.

[98]  D. O'Connor,et al.  Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. , 1995, Hypertension.

[99]  D. Averill,et al.  Losartan, nonpeptide angiotensin II-type 1 (AT1) receptor antagonist, attenuates pressor and sympathoexcitatory responses evoked by angiotensin II andL-glutamate in rostral ventrolateral medulla , 1994, Brain Research.

[100]  B. Karlberg,et al.  Effects of modulators of the renin—angiotensin—aldosterone system on cough , 1994, Journal of hypertension.

[101]  Hiroaki Tanaka,et al.  Angiotensin II formation by an alternative pathway during exercise in humans , 1994, Journal of hypertension.

[102]  Å. Hjalmarson,et al.  Beta-blocker treatment for chronic heart failure. The frog prince. , 1994, Circulation.

[103]  T. Lüscher,et al.  Angiotensin Blockade or Calcium Antagonists Improve Endothelial Dysfunction in Hypertension: Studies in Perfused Mesenteric Resistance Arteries , 1994, Journal of cardiovascular pharmacology.

[104]  H. Chen,et al.  Physical Conditioning Decreases Norepinephrine‐Induced Vasoconstriction in Rabbits: Possible Roles of Norepinephrine‐Evoked Endothelium‐Derived Relaxing Factor , 1994, Circulation.

[105]  A. Malliani,et al.  Sympathetic restraint of baroreflex control of heart period in normotensive and hypertensive subjects. , 1994, Clinical science.

[106]  Trefor Owen Morgan Clinical Pharmacokinetics and Pharmacodynamics of Carvedilol , 1994, Clinical pharmacokinetics.

[107]  S. Julius,et al.  Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. , 1994, Journal of hypertension.

[108]  T. Lüscher,et al.  Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. , 1994, Circulation.

[109]  K. Matsubayashi,et al.  [Effect of nifedipine and enalapril on cardiac autonomic activity in elderly hypertensive patients]. , 1994, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[110]  A. Daul,et al.  Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment. , 1994, Journal of the American College of Cardiology.

[111]  P. Ernsberger,et al.  A novel mechanism of action for hypertension control: Moxonidine as a selective I1-imidazoline agonist , 1994, Cardiovascular Drugs and Therapy.

[112]  P. Schollmeyer,et al.  Effects of imidazolines on noradrenaline release in rat isolated kidney , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[113]  U. Goldbourt,et al.  Immediate and long-term prognostic significance of a first anterior versus first inferior wall Q-wave acute myocardial infarction , 1993 .

[114]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[115]  P. Dominiak Modulation of sympathetic control by ACE inhibitors. , 1993, European heart journal.

[116]  H. Brasch,et al.  Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. , 1993, Hypertension.

[117]  M. Thames,et al.  Abnormalities of baroreflex control in heart failure. , 1993, Journal of the American College of Cardiology.

[118]  P. Mannucci,et al.  Desmopressin and blood loss after cardiac surgery , 1993, The Lancet.

[119]  T. Lüscher,et al.  Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. , 1993, Circulation.

[120]  T. Mano,et al.  Elevated sympathetic nerve activity in patients with accelerated essential hypertension. , 1993, The Journal of clinical investigation.

[121]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[122]  J. Osborn,et al.  Neurogenic control of renal function in response to graded nonhypotensive hemorrhage in conscious dogs. , 1993, The American journal of physiology.

[123]  G. Gensini,et al.  Silent Ischemia in Unstable Angina Is Related to an Altered Cardiac Norepinephrine Handling , 1993, Circulation.

[124]  F. Luft,et al.  Angiotensin II facilitates sympathetic transmission in rat hind limb circulation. , 1993, Hypertension.

[125]  M. Kienzle,et al.  Muscle Sympathetic Nerve Activity Is Reduced in IDDM Before Overt Autonomic Neuropathy , 1993, Diabetes.

[126]  R. Converse,et al.  Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.

[127]  M. Burnier,et al.  Neurohormonal consequences of diuretics in different cardiovascular syndromes. , 1992, European heart journal.

[128]  D. Harron,et al.  The effects of rilmenidine on tests of autonomic function in humans , 1992, Clinical pharmacology and therapeutics.

[129]  I. Gavras Bradykinin-mediated effects of ACE inhibition. , 1992, Kidney international.

[130]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[131]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[132]  J. Dimsdale,et al.  Converting enzyme inhibition and blood pressure reactivity to psychological stressors. , 1992, Hypertension.

[133]  W. Hall,et al.  Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy , 1992, Annals of Internal Medicine.

[134]  O. Parsons,et al.  Cardiovascular differentiation of emotions. , 1992, Psychosomatic medicine.

[135]  W. J. van der Giessen,et al.  Effect of Epinine on Systemic Hemodynamics and Regional Blood Flow in Conscious Pigs , 1992, Journal of cardiovascular pharmacology.

[136]  E. Krieger,et al.  Early depression of the baroreceptor sensitivity during onset of hypertension. , 1992, Hypertension.

[137]  S. Oparil,et al.  Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. , 1992, Hypertension.

[138]  M. Schlepper,et al.  Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension , 1991, Cardiovascular Drugs and Therapy.

[139]  W. Koenig,et al.  Catecholamines and the Renin‐Angiotensin‐Aldosterone System During Treatment with Felodipine ER or Hydrochlorothiazide in Essential Hypertension , 1991, Journal of cardiovascular pharmacology.

[140]  I. Meredith,et al.  Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. , 1991, The New England journal of medicine.

[141]  W. Littler,et al.  Effects of the angiotensin converting enzyme inhibitor, benazepril, on the sino-aortic baroreceptor heart rate reflex , 1991, Cardiovascular Drugs and Therapy.

[142]  A. Malliani,et al.  Cardiovascular Neural Regulation Explored in the Frequency Domain , 1991, Circulation.

[143]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[144]  H. Kannan,et al.  Effects of centrally administered angiotensin on sympathetic nerve activity and blood flow to the kidney in conscious rats. , 1991, Journal of the autonomic nervous system.

[145]  J. Dimsdale,et al.  Cardiovascular reactivity to psychosocial stressors. A review of the effects of beta-blockade. , 1991, Psychosomatics.

[146]  D. Ardissino,et al.  Transient myocardial ischemia during daily life in rest and exertional angina pectoris and comparison of effectiveness of metoprolol versus nifedipine. , 1991, The American journal of cardiology.

[147]  R. Prager,et al.  Metabolic Effects of Isradipine Versus Hydrochlorothiazide in Diabetes Mellitus , 1991, Hypertension.

[148]  O. Tochikubo,et al.  Augmented sympathetic nerve activity in response to stressors in young borderline hypertensive men. , 1991, Acta physiologica Scandinavica.

[149]  T. Lüscher,et al.  Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. , 1991, Circulation.

[150]  K. Misono,et al.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.

[151]  J. Mehta,et al.  Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. , 1990, The American journal of cardiology.

[152]  R. Dietz,et al.  ACE inhibition improves vagal reactivity in patients with heart failure. , 1990, American heart journal.

[153]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[154]  K. Swedberg,et al.  Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. , 1990, The American journal of cardiology.

[155]  I. Meredith,et al.  Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. , 1990, Physiological reviews.

[156]  S. Malpas,et al.  Heart-Rate Variability and Cardiac Autonomic Function in Diabetes , 1990, Diabetes.

[157]  J. Loscalzo,et al.  Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. , 1990, The Journal of clinical investigation.

[158]  J. Deckers,et al.  Retardation of angiographic progression of coronary artery disease by nifedipine , 1990, The Lancet.

[159]  I. J. Kopin,et al.  Positron emission tomographic imaging of cardiac sympathetic innervation and function. , 1990, Circulation.

[160]  D. Renlund,et al.  Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. , 1990, The American journal of medicine.

[161]  C. Furberg,et al.  Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. , 1989, BMJ.

[162]  D. Ferguson,et al.  Nifedipine potentiates cardiopulmonary baroreflex control of sympathetic nerve activity in healthy humans. Direct evidence from microneurographic studies. , 1989, Circulation.

[163]  E A Anderson,et al.  Elevated Sympathetic Nerve Activity in Borderline Hypertensive Humans Evidence From Direct Intraneural Recordings , 1989, Hypertension.

[164]  O. Tochikubo,et al.  Age‐Related Changes in Muscle Sympathetic Nerve Activity in Essential Hypertension , 1989, Hypertension.

[165]  N. Matsuki,et al.  Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[166]  M. Dontenwill,et al.  The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. , 1989, European journal of pharmacology.

[167]  H. Motulsky,et al.  [3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site. , 1989, Molecular pharmacology.

[168]  J. Forfar,et al.  Cardiac and whole body [3H]noradrenaline kinetics in ischaemic heart disease: contrast between unstable anginal syndromes and pacing induced ischaemia. , 1989, British heart journal.

[169]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[170]  D. Ferguson,et al.  Diastolic pressure determines autonomic responses to pressure perturbation in humans. , 1989, Journal of applied physiology.

[171]  J. Laragh,et al.  Assessment of the effects of alpha- and beta-blockade in hypertensive patients who smoke cigarettes. , 1989, The American journal of medicine.

[172]  J. Hall,et al.  Interactions between angiotensin II and renal nerves during chronic sodium deprivation. , 1988, The American journal of physiology.

[173]  M. Packer Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. , 1988, Journal of the American College of Cardiology.

[174]  B. Fabris,et al.  Arterial compliance and baroreceptor sensitivity after chronic treatment with indapamide. , 1988, Journal of human hypertension.

[175]  J. Tuomilehto,et al.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. , 1988, JAMA.

[176]  S. Julius,et al.  The blood pressure seeking properties of the central nervous system. , 1988, Journal of hypertension.

[177]  C. Dollery Advantages and disadvantages of alpha 2-adrenoceptor agonists for systemic hypertension. , 1988, The American journal of cardiology.

[178]  C. Dollery,et al.  Dose and concentration-effect relations for rilmenidine. , 1988, The American journal of cardiology.

[179]  E. Johns,et al.  The role of angiotensin II in the renal responses to somatic nerve stimulation in the rat. , 1987, The Journal of physiology.

[180]  B. Wallin,et al.  Muscle sympathetic activity and venous plasma noradrenaline concentrations during static exercise in normotensive and hypertensive subjects. , 1987, Acta physiologica Scandinavica.

[181]  S. Dombey,et al.  Post marketing surveillance of captopril (for hypertension): a preliminary report. , 1987, British journal of clinical pharmacology.

[182]  J. Izzo,et al.  Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. , 1987, The American journal of cardiology.

[183]  A. Mark,et al.  Effects of the cold pressor test on muscle sympathetic nerve activity in humans. , 1987, Hypertension.

[184]  E. Nabel,et al.  Circadian rhythms and coronary artery disease. , 1987, The American journal of cardiology.

[185]  J. Viersma,et al.  Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Report of The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. , 1986, British heart journal.

[186]  H. Rüddel,et al.  Hemodynamic and Neurohumoral Effects of Low‐Dose Clonidine in Mild to Moderate Hypertension , 1986, Journal of cardiovascular pharmacology.

[187]  J. Izzo,et al.  Increased Plasma Norepinephrine and Sympathetic Nervous Activity in Essential Hypertensive and Uremic Humans: Effects of Clonidine , 1986, Journal of cardiovascular pharmacology.

[188]  M. Turiel,et al.  Power Spectral Analysis of Heart Rate and Arterial Pressure Variabilities as a Marker of Sympatho‐Vagal Interaction in Man and Conscious Dog , 1986, Circulation research.

[189]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[190]  P. Pandhi,et al.  Comparative effect of propranolol and labetalol on isometric exercise and cold stress induced increase in arterial blood pressure. , 1986, International journal of clinical pharmacology, therapy, and toxicology.

[191]  A. Mark,et al.  Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. , 1986, Circulation.

[192]  J. Rouleau,et al.  Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. , 1986, Circulation.

[193]  R. Cohen,et al.  Hemodynamic regulation: investigation by spectral analysis. , 1985, The American journal of physiology.

[194]  R. Gunnar,et al.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.

[195]  A. Mark,et al.  Microneurographic studies of the mechanisms of sympathetic nerve responses to static exercise in humans. , 1985, Circulation research.

[196]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[197]  B. Wallin,et al.  Sympathetic outflow to muscles during treatment of hypertension with metoprolol. , 1984, Hypertension.

[198]  S. H. Koenig,et al.  Prazosin as initial antihypertensive therapy: correlates of sympathetic function. , 1984, The American journal of cardiology.

[199]  D. Reis,et al.  Lesions of Epinephrine Neurons in the Rostral Ventrolateral Medulla Abolish the Vasodepressor Components of Baroreflex and Cardiopulmonary Reflex , 1983, Hypertension.

[200]  J. Angus,et al.  Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin , 1983, Nature.

[201]  B. Wallin,et al.  Acute effects of metoprolol on muscle sympathetic activity in hypertensive humans. , 1983, Hypertension.

[202]  A. Spiers,et al.  HAEMORRHAGIC CYSTITIS AFTER LOW-DOSE CYCLOSPHOSPHAMIDE , 1983, The Lancet.

[203]  A. Semplicini,et al.  Alpha‐adrenoceptor blockade by labetalol during long‐term dosing , 1983, Clinical pharmacology and therapeutics.

[204]  T. Thien,et al.  Effect of low‐dose epinephrine infusion on hemodynamics after selective and nonselective β‐blockade in hypertension , 1982 .

[205]  B. Folkow Physiological aspects of primary hypertension. , 1982, Physiological reviews.

[206]  B. Wallin,et al.  The Antihypertensive Mechanism of Clonidine in Man: Evidence Against a Generalized Reduction of Sympathetic Activity , 1981, Hypertension.

[207]  A. Vallbo,et al.  Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. , 1979, Physiological reviews.

[208]  I. Kopin,et al.  Hydrochlorothiazide‐induced sympathetic hyperactivity in hypertensive patients , 1979, Clinical pharmacology and therapeutics.

[209]  T. Philipp,et al.  SYMPATHETIC NERVOUS SYSTEM AND BLOOD-PRESSURE CONTROL IN ESSENTIAL HYPERTENSION , 1978, The Lancet.

[210]  D. Eckberg,et al.  Respiratory and baroreceptor reflex interactions in man. , 1977, The Journal of clinical investigation.

[211]  D. Richards,et al.  Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects. , 1977, British journal of clinical pharmacology.

[212]  B Lown,et al.  Neural activity and ventricular fibrillation. , 1976, The New England journal of medicine.

[213]  Q. Regestein,et al.  Basis for recurring ventricular fibrillation in the absence of coronary heart disease and its management. , 1976, The New England journal of medicine.

[214]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[215]  S. Oram,et al.  MODIFICATION BY PROPRANOLOL OF CARDIOVASCULAR EFFECTS OF INDUCED HYPOGLYCÆMIA , 1975, The Lancet.

[216]  R. Tarazi,et al.  Cardiac Hypertrophy in Spontaneously Hypertensive Rats , 1974, Circulation research.

[217]  W. Nayler,et al.  Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. , 1972, Cardiovascular research.

[218]  S. Julius,et al.  Role of Parasympathetic Inhibition in the Hyperkinetic Type of Borderline Hypertension , 1971, Circulation.

[219]  M. Ulrych Changes of general haemodynamics during stressful mental arithmetic and non-stressing quiet conversation and modification of the latter by beta-adrenergic blockade. , 1969, Clinical science.

[220]  A. P. Shapiro Pressor responses to noxious stimuli in hypertensive patients. Effects of reserpine and chlorothiazide. , 1962 .

[221]  A. P. Shapiro Pressor Responses to Noxious Stimuli in Hypertensive Patients: Effects of Reserpine and Chlorothiazide , 1962, Circulation.

[222]  A. Doyle,et al.  The Neurogenic Component in Hypertension , 1955, Circulation.

[223]  Beretta-Piccoli,et al.  Plasma Catecholamines and Essential Hypertension An Analytical Review , 2005 .

[224]  K. Dickstein,et al.  Plasma Endothelin Determination as a Prognostic Indicator of 1-Year Mortalit After Acute Myocardial Infarction , 2005 .

[225]  F. Veglio,et al.  Heart Rate Variability and Baroreflex Sensitivity during Fosinopril, Irbesartan and Atenolol Therapy in Hypertension , 2004, Clinical drug investigation.

[226]  M. Searle,et al.  Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial , 2004, European Journal of Clinical Pharmacology.

[227]  H. Black Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials. , 2004, Clinical cornerstone.

[228]  S. Umemura,et al.  Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. , 2004, American journal of hypertension.

[229]  P. Turner,et al.  Preliminary clinical pharmacological studies of S3341, a new hypotensive agent, and comparison with clonidine in normal males , 2004, European Journal of Clinical Pharmacology.

[230]  G. Belz,et al.  Systolic time intervals in clinical pharmacology , 2004, European Journal of Clinical Pharmacology.

[231]  L. Gerber,et al.  Low-dose alpha/beta blockade in the treatment of essential hypertension. , 2001, American journal of hypertension.

[232]  P. V. van Zwieten The renaissance of centrally acting antihypertensive drugs. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[233]  G Mancia,et al.  Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. , 1998, Hypertension.

[234]  Guido Grassi,et al.  Antihypertensive treatment: past, present and future. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[235]  K. Arakawa,et al.  Amlodipine lowers blood pressure without increasing sympathetic activity or activating the renin-angiotensin system in patients with essential hypertension , 1997, European Journal of Clinical Pharmacology.

[236]  H. Küppers,et al.  Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. , 1997, Journal of hypertension.

[237]  T. Thien,et al.  Effects of acute and chronic angiotensin converting enzyme inhibition by spirapril on cardiovascular regulation in essential hypertensive patients. Assessment by spectral analysis and haemodynamic measurements. , 1996, British journal of clinical pharmacology.

[238]  J. Elghozi,et al.  Effects of beta-adrenergic blockade on short-term variability of blood pressure and heart rate in essential hypertension. , 1995, Clinical and experimental hypertension.

[239]  K. Sugimoto,et al.  Effect of an angiotensin receptor antagonist, TCV-116, on sympathetic nerve activity in patients with essential hypertension. , 1994, Blood pressure. Supplement.

[240]  T. Inagami,et al.  Endothelin as a neuropeptide. Cardiovascular effects in the brainstem of normotensive rats. , 1993, Circulation research.

[241]  P. Ernsberger,et al.  Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. , 1993, The Journal of pharmacology and experimental therapeutics.

[242]  P. Saxena Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. , 1992, Journal of cardiovascular pharmacology.

[243]  S. Julius,et al.  Early Association of Sympathetic Overactivity, Hypertension, Insulin Resistance, and Coronary Risk , 1992, Journal of cardiovascular pharmacology.

[244]  G. Jennings,et al.  Regional norepinephrine turnover in human hypertension. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.

[245]  W. Anderson,et al.  Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. , 1988, Hypertension.

[246]  G. Parati,et al.  Effects of celiprolol on reflex control of the cardiovascular system in essential hypertension. , 1986, Journal of cardiovascular pharmacology.

[247]  F. Messerli,et al.  Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. , 1986, Circulation.

[248]  Datey Kk,et al.  Effect of isometric exercise and mental stress on blood pressure--comparative effects of propranolol and labetalol. , 1984, Indian heart journal.

[249]  F. Abboud The sympathetic nervous system in hypertension. , 1984, Clinical and experimental hypertension. Part A, Theory and practice.

[250]  O. Brodde,et al.  Subclassification of human beta-adrenergic receptors mediating renin release. , 1983, Clinical and experimental hypertension. Part A, Theory and practice.

[251]  J. Laragh,et al.  Plasma catecholamines and cardiovascular responses during converting enzyme inhibition in normotensive and hypertensive man. , 1982, Clinical and experimental hypertension. Part A, Theory and practice.

[252]  J. de Champlain,et al.  Evidences supporting an increased sympathetic tone and reactivity in a subgroup of patients with essential hypertension. , 1980, Clinical and experimental hypertension.

[253]  J. O. Davis,et al.  Mechanisms regulating renin release. , 1976, Physiological reviews.

[254]  K. Hagbarth,et al.  Manoeuvres affecting sympathetic outflow in human skin nerves. , 1972, Acta physiologica Scandinavica.